Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 140.8%

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 11,335 shares, a growth of 140.8% from the February 26th total of 4,707 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 5,784 shares, the days-to-cover ratio is presently 2.0 days.

PureTech Health Trading Up 0.0%

Shares of PureTech Health stock opened at $15.74 on Thursday. The firm has a fifty day moving average of $17.66 and a two-hundred day moving average of $17.30. PureTech Health has a 52 week low of $13.30 and a 52 week high of $20.00.

Institutional Investors Weigh In On PureTech Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRTC. Diadema Partners LP acquired a new position in PureTech Health in the second quarter valued at about $126,000. Pentwater Capital Management LP grew its position in shares of PureTech Health by 50.0% during the 3rd quarter. Pentwater Capital Management LP now owns 75,000 shares of the company’s stock worth $1,388,000 after buying an additional 25,000 shares during the period. Finally, Lansdowne Partners UK LLP bought a new stake in shares of PureTech Health in the 3rd quarter valued at about $260,973,000. Institutional investors own 0.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d)” rating on shares of PureTech Health in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

About PureTech Health

PureTech Health (NASDAQ: PRTC) is a clinical-stage biotherapeutics company focused on creating and developing first-in-class medicines across immunology, inflammation, oncology and neuroscience. The company operates through a model of incubating programs in-house and advancing selected assets into independent, value-creating entities. Its internal pipeline includes multiple clinical and preclinical candidates addressing fibrotic diseases, solid tumors and rare genetic disorders.

PureTech’s proprietary platform technologies span modalities such as monoclonal antibodies, small molecules and cell-based therapies.